Enzyme Breakthrough Sparks Hope for Jaw Arthritis Treatment

LOXL2 enzyme found to play critical role in maintaining cartilage health and preventing osteoarthritis in the temporomandibular joint.

Published on Mar. 7, 2026

Got story updates? Submit your updates here. ›

Researchers from Boston University have made a significant discovery about the role of the enzyme lysyl oxidase-like 2 (LOXL2) in maintaining healthy cartilage and preventing the development of temporomandibular joint osteoarthritis (TMJ-OA). Their findings, published in the International Journal of Oral Science, show that LOXL2 helps suppress inflammatory pathways, protect cartilage cells, and preserve the structural integrity of the joint. This breakthrough could lead to the development of targeted therapies for TMJ disorders.

Why it matters

TMJ-OA is a common and debilitating condition that affects the cartilage and joint connecting the lower jaw to the skull, causing pain, stiffness, and decreased mobility. However, there are currently no FDA-approved drugs specifically designed to protect or regenerate cartilage in this joint. This discovery of LOXL2's critical role in maintaining healthy cartilage could pave the way for new treatments to slow or even stop the progression of TMJ-OA.

The details

The study, led by Assistant Professor Manish V. Bais from Boston University, used genetically modified mice and cartilage samples from goats to analyze the role of LOXL2. They found that the loss of LOXL2 activates inflammatory genes and weakens the cartilage by reducing its essential structural components. LOXL2 helps suppress the NF-κB pathway, which is a "master switch" for inflammation, and also protects the cartilage cells' mitochondria from inflammatory attacks. When cartilage samples were treated with additional LOXL2, the enzyme reversed many harmful effects caused by inflammation, reducing the expression of molecules linked to pain and cartilage destruction.

  • The study's findings were made available online in the International Journal of Oral Science on February 4, 2026.

The players

Manish V. Bais

An Associate Professor of Translational Dental Medicine at Boston University's Henry M. Goldman School of Dental Medicine, where he leads the Bais lab, which focuses on translational research at the intersection of cancer biology, regenerative medicine, and immunology.

Boston University

A leading private research institution in Boston, Massachusetts, founded in 1839, with more than 37,000 students from over 140 countries, dedicated to advancing knowledge across diverse fields.

Got photos? Submit your photos here. ›

What they’re saying

“Cartilage deterioration is a hallmark of osteoarthritis.”

— Manish V. Bais, Associate Professor (International Journal of Oral Science)

“We observed that the loss of loxl2 activates inflammatory genes and weakens the cartilage by reducing its essential structural components such as aggrecanproteoglycans and promote inflammatory factors.”

— Manish V. Bais, Associate Professor (International Journal of Oral Science)

“Our findings identify LOXL2 as a promising therapeutic target for TMJ disorders. By safeguarding cartilage and preventing cell death, this enzyme may have the potential to slow down or even stop the progression of arthritis in the jaw.”

— Manish V. Bais, Associate Professor (International Journal of Oral Science)

What’s next

The authors acknowledge the need for additional clinical studies to confirm these effects in humans, but this study marks a significant step towards developing targeted therapies for TMJ disorders.

The takeaway

This breakthrough discovery of LOXL2's critical role in maintaining healthy cartilage and preventing osteoarthritis in the temporomandibular joint could lead to the development of new treatments to help patients with TMJ disorders preserve joint function, reduce pain, and improve their overall quality of life.